SK6592000A3 - Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances - Google Patents

Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances Download PDF

Info

Publication number: SK6592000A3
Authority: SK; Slovakia
Prior art keywords: oily; delivery composition; pharmaceutical active; composition according; sticky
Prior art date: 1997-11-28

Application number

SK659-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Christer Karlsson

Per Johan Lundberg

Adam Rosinski

Malin Soderbom

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-11-28

Filing date

1998-11-18

Publication date

2001-01-18

1998-11-18 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2001-01-18 Publication of SK6592000A3 publication Critical patent/SK6592000A3/sk

Links

239000011159 matrix material Substances 0.000 title claims abstract description 21
229920001223 polyethylene glycol Polymers 0.000 title claims description 23
239000002202 Polyethylene glycol Substances 0.000 title claims description 14
229940088679 drug related substance Drugs 0.000 title 1
239000008188 pellet Substances 0.000 title 1
239000000126 substance Substances 0.000 claims abstract description 28
239000013543 active substance Substances 0.000 claims abstract description 25
239000007787 solid Substances 0.000 claims abstract description 23
238000012377 drug delivery Methods 0.000 claims abstract description 7
238000002360 preparation method Methods 0.000 claims abstract description 4
239000008187 granular material Substances 0.000 claims description 35
239000000203 mixture Substances 0.000 claims description 32
239000003814 drug Substances 0.000 claims description 27
229920000642 polymer Polymers 0.000 claims description 24
RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical group CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims description 15
229940079593 drug Drugs 0.000 claims description 15
229960003580 felodipine Drugs 0.000 claims description 15
239000002245 particle Substances 0.000 claims description 12
239000000839 emulsion Substances 0.000 claims description 8
239000007788 liquid Substances 0.000 claims description 8
DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical group C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 claims description 7
229960002137 melagatran Drugs 0.000 claims description 7
239000000725 suspension Substances 0.000 claims description 7
230000001050 lubricating effect Effects 0.000 claims description 5
-1 dihydropyridine compound Chemical class 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 3
OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 2
108090000190 Thrombin Proteins 0.000 claims description 2
229940062527 alendronate Drugs 0.000 claims description 2
230000002401 inhibitory effect Effects 0.000 claims description 2
239000000314 lubricant Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
108090000765 processed proteins & peptides Proteins 0.000 claims description 2
229960004072 thrombin Drugs 0.000 claims description 2
230000009466 transformation Effects 0.000 claims 1
238000000034 method Methods 0.000 abstract description 10
239000011324 bead Substances 0.000 abstract 2
229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 11
229920002261 Corn starch Polymers 0.000 description 9
238000004090 dissolution Methods 0.000 description 9
229940093429 polyethylene glycol 6000 Drugs 0.000 description 9
238000010521 absorption reaction Methods 0.000 description 8
239000008120 corn starch Substances 0.000 description 8
239000012738 dissolution medium Substances 0.000 description 8
239000002552 dosage form Substances 0.000 description 8
239000000843 powder Substances 0.000 description 8
ZMHOBBKJBYLXFR-BPNWFJGMSA-N 4-[(2r)-3-[ethyl(3-propylsulfinylpropyl)amino]-2-hydroxypropoxy]benzonitrile Chemical compound CCCS(=O)CCCN(CC)C[C@@H](O)COC1=CC=C(C#N)C=C1 ZMHOBBKJBYLXFR-BPNWFJGMSA-N 0.000 description 7
229950003699 almokalant Drugs 0.000 description 7
238000003756 stirring Methods 0.000 description 7
238000010438 heat treatment Methods 0.000 description 6
239000002609 medium Substances 0.000 description 6
239000002904 solvent Substances 0.000 description 6
239000003623 enhancer Substances 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
239000004094 surface-active agent Substances 0.000 description 4
239000004809 Teflon Substances 0.000 description 3
229920006362 Teflon® Polymers 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000007789 gas Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
238000007711 solidification Methods 0.000 description 3
230000008023 solidification Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
238000000870 ultraviolet spectroscopy Methods 0.000 description 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000009826 distribution Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
229940068918 polyethylene glycol 400 Drugs 0.000 description 2
239000004848 polyfunctional curative Substances 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
BNZPFJBUHRBLNB-UHFFFAOYSA-N 1-oxido-1,2,4-benzotriazin-1-ium Chemical compound C1=CC=C2[N+]([O-])=NC=NC2=C1 BNZPFJBUHRBLNB-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
CDPROXZBMHOBTQ-SJORKVTESA-N 2-[[(2r)-3-cyclohexyl-1-[(2s)-2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetic acid Chemical compound NC(N)=NCCCNC(=O)[C@@H]1CCCCN1C(=O)[C@H](NCC(O)=O)CC1CCCCC1 CDPROXZBMHOBTQ-SJORKVTESA-N 0.000 description 1
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
239000008118 PEG 6000 Substances 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
229920003171 Poly (ethylene oxide) Chemical class 0.000 description 1
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000003570 air Substances 0.000 description 1
DNEHKUCSURWDGO-UHFFFAOYSA-N aluminum sodium Chemical compound [Na].[Al] DNEHKUCSURWDGO-UHFFFAOYSA-N 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
239000003911 antiadherent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000000149 argon plasma sintering Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
238000005354 coacervation Methods 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
125000004925 dihydropyridyl group Chemical class N1(CC=CC=C1)* 0.000 description 1
238000007922 dissolution test Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000011049 filling Methods 0.000 description 1
230000030136 gastric emptying Effects 0.000 description 1
210000005095 gastrointestinal system Anatomy 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
239000002628 heparin derivative Substances 0.000 description 1
239000002634 heparin fragment Substances 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229950003291 inogatran Drugs 0.000 description 1
230000001788 irregular Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000008180 pharmaceutical surfactant Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000007712 rapid solidification Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
239000008137 solubility enhancer Substances 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000001360 synchronised effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Landscapes

Health & Medical Sciences (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK659-2000A 1997-11-28 1998-11-18 Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances SK6592000A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9704401A SE9704401D0 (sv)	1997-11-28	1997-11-28	Matrix pellets for greasy, oily or sticky drug substances
PCT/SE1998/002090 WO1999027913A1 (en)	1997-11-28	1998-11-18	Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances

Publications (1)

Publication Number	Publication Date
SK6592000A3 true SK6592000A3 (en)	2001-01-18

Family

ID=20409178

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK659-2000A SK6592000A3 (en)	1997-11-28	1998-11-18	Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances

Country Status (23)

Country	Link
US (2)	US6555138B1 (de)
EP (1)	EP1032371B1 (de)
JP (1)	JP2001524514A (de)
KR (1)	KR20010032558A (de)
CN (1)	CN1280493A (de)
AR (1)	AR016684A1 (de)
AT (1)	ATE286382T1 (de)
AU (1)	AU746324B2 (de)
BR (1)	BR9814756A (de)
CA (1)	CA2311930A1 (de)
DE (1)	DE69828527T2 (de)
HU (1)	HUP0004405A3 (de)
ID (1)	ID24185A (de)
IL (1)	IL136144A0 (de)
NO (1)	NO20002720L (de)
NZ (1)	NZ504354A (de)
PL (1)	PL340926A1 (de)
RU (1)	RU2216316C2 (de)
SE (1)	SE9704401D0 (de)
SK (1)	SK6592000A3 (de)
TW (1)	TW570813B (de)
WO (1)	WO1999027913A1 (de)
ZA (1)	ZA9810465B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6515009B1 (en)	1991-09-27	2003-02-04	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en)	1993-01-28	1998-09-22	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
SE9704401D0 (sv) *	1997-11-28	1997-11-28	Astra Ab	Matrix pellets for greasy, oily or sticky drug substances
IT1319202B1 (it)	2000-10-12	2003-09-26	Nicox Sa	Farmaci per le malattie a base infiammatoria.
US6462021B1 (en)	2000-11-06	2002-10-08	Astrazeneca Ab	Use of low molecular weight thrombin inhibitor
AR035216A1 (es)	2000-12-01	2004-05-05	Astrazeneca Ab	Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US6613083B2 (en)	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
SE0201658D0 (sv) *	2002-05-31	2002-05-31	Astrazeneca Ab	Immediate release pharmaceutical formulation
JP3887588B2 (ja) *	2002-08-30	2007-02-28	株式会社リガク	Ｘ線回折による応力測定法
US8986737B2 (en)	2002-09-05	2015-03-24	Wm. Marsh Rice University	Antibiotic microspheres for treatment and prevention of osteomyelitis and enhancement of bone regrowth
AU2003302238A1 (en)	2002-12-03	2004-06-23	Axys Pharmaceuticals, Inc.	2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
US20070059358A1 (en) *	2003-07-02	2007-03-15	Tianjin Tasly Pharmaceutical Co., Ltd., China	Matrix adjuvants and the drop pills prepared with them
WO2008008120A1 (en) *	2006-07-14	2008-01-17	Fmc Corporation	Solid form
WO2008074145A1 (en) *	2006-12-20	2008-06-26	Genpharm Ulc	Pharmaceutical composition comprising a hot-melt granulated lubricant
AU2014201170B2 (en) *	2006-12-20	2015-09-24	Mylan Pharmaceuticals Ulc	Pharmaceutical composition comprising a hot-melt granulated lubricant
US20080311162A1 (en) *	2007-05-16	2008-12-18	Olivia Darmuzey	Solid form
JP6641265B2 (ja)	2013-09-19	2020-02-05	マイクロベンションインコーポレイテッドＭｉｃｒｏｖｅｎｔｉｏｎ，Ｉｎｃ．	ポリマーフィルム
EP3046952B1 (de)	2013-09-19	2021-05-12	Terumo Corporation	Polymerpartikel
EP3065719A4 (de)	2013-11-08	2017-08-09	Terumo Corporation	Polymerpartikel
CN104133014B (zh) *	2014-07-16	2015-09-16	广州法尔麦兰药物技术有限公司	一种考察布洛伪麻缓释制剂释放度的方法
WO2016154592A1 (en)	2015-03-26	2016-09-29	Microvention, Inc.	Embiolic particles
EP4279139A3 (de)	2016-09-28	2024-01-24	Terumo Corporation	Polymerpartikel

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE557670C (de)		1932-08-26	Friedrich Rittershausen	Abtast- bzw. Bildzusammensetzvorrichtung
DE454386C (de)	1924-05-27	1928-01-06	Chemische Produkte Vormals H S	Verfahren zur Herstellung pharmazeutischer und diaetetischer Praeparate in kugelaehnlicher Form
US2699054A (en)	1953-10-09	1955-01-11	Lloyd H Conover	Tetracycline
DE2251197C3 (de)	1972-10-19	1980-05-08	Hoechst Ag, 6000 Frankfurt	Verfahren zur Herstellung von hxxochdosierten Tabletten von Tetracyclin- Derivaten
GB8613689D0 (en) *	1986-06-05	1986-07-09	Euro Celtique Sa	Pharmaceutical composition
DE3636123A1 (de) *	1986-10-23	1988-05-05	Rentschler Arzneimittel	Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten
US5051261A (en) *	1987-11-24	1991-09-24	Fmc Corporation	Method for preparing a solid sustained release form of a functionally active composition
ATE76292T1 (de) *	1987-11-25	1992-06-15	American Cyanamid Co	System fuer die verzoegerte (kontrollierte) freisetzung von substituierten dihydropyridincalciumantagonisten.
US5876754A (en) *	1992-01-17	1999-03-02	Alfatec-Pharma Gmbh	Solid bodies containing active substances and a structure consisting of hydrophilic macromolecules, plus a method of producing such bodies
ES2092808T3 (es) *	1992-01-17	1996-12-01	Alfatec Pharma Gmbh	Cuerpos solidos con contenido en principio activo con una estructura a base de macromoleculas hidrofilas y procedimiento para su produccion.
ATE179606T1 (de) *	1992-02-25	1999-05-15	Spirig Ag	Minocyclin enthaltende pellets
US5431920A (en) *	1993-09-21	1995-07-11	Merck Frosst, Canada, Inc.	Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
SE9704401D0 (sv) *	1997-11-28	1997-11-28	Astra Ab	Matrix pellets for greasy, oily or sticky drug substances

1997
- 1997-11-28 SE SE9704401A patent/SE9704401D0/xx unknown
1998
- 1998-10-27 TW TW087117778A patent/TW570813B/zh active
- 1998-11-16 AR ARP980105800A patent/AR016684A1/es not_active Application Discontinuation
- 1998-11-16 ZA ZA9810465A patent/ZA9810465B/xx unknown
- 1998-11-18 PL PL98340926A patent/PL340926A1/xx unknown
- 1998-11-18 JP JP2000522899A patent/JP2001524514A/ja active Pending
- 1998-11-18 HU HU0004405A patent/HUP0004405A3/hu unknown
- 1998-11-18 SK SK659-2000A patent/SK6592000A3/sk unknown
- 1998-11-18 WO PCT/SE1998/002090 patent/WO1999027913A1/en not_active Ceased
- 1998-11-18 NZ NZ504354A patent/NZ504354A/en unknown
- 1998-11-18 US US09/214,317 patent/US6555138B1/en not_active Expired - Fee Related
- 1998-11-18 DE DE69828527T patent/DE69828527T2/de not_active Expired - Lifetime
- 1998-11-18 RU RU2000113730/14A patent/RU2216316C2/ru not_active IP Right Cessation
- 1998-11-18 EP EP98957269A patent/EP1032371B1/de not_active Expired - Lifetime
- 1998-11-18 IL IL13614498A patent/IL136144A0/xx unknown
- 1998-11-18 ID IDW20000913A patent/ID24185A/id unknown
- 1998-11-18 CA CA002311930A patent/CA2311930A1/en not_active Abandoned
- 1998-11-18 AT AT98957269T patent/ATE286382T1/de not_active IP Right Cessation
- 1998-11-18 KR KR1020007005803A patent/KR20010032558A/ko not_active Withdrawn
- 1998-11-18 CN CN98811637A patent/CN1280493A/zh active Pending
- 1998-11-18 BR BR9814756-0A patent/BR9814756A/pt not_active IP Right Cessation
- 1998-11-19 AU AU13564/99A patent/AU746324B2/en not_active Ceased
2000
- 2000-05-26 NO NO20002720A patent/NO20002720L/no unknown
2003
- 2003-03-11 US US10/385,926 patent/US20030175352A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE69828527D1 (de)	2005-02-10
US20030175352A1 (en)	2003-09-18
NO20002720D0 (no)	2000-05-26
AU1356499A (en)	1999-06-16
AU746324B2 (en)	2002-04-18
SE9704401D0 (sv)	1997-11-28
ID24185A (id)	2000-07-13
HUP0004405A2 (hu)	2001-08-28
ATE286382T1 (de)	2005-01-15
CA2311930A1 (en)	1999-06-10
CN1280493A (zh)	2001-01-17
TW570813B (en)	2004-01-11
BR9814756A (pt)	2000-10-03
KR20010032558A (ko)	2001-04-25
US6555138B1 (en)	2003-04-29
EP1032371B1 (de)	2005-01-05
EP1032371A1 (de)	2000-09-06
NO20002720L (no)	2000-07-28
IL136144A0 (en)	2001-05-20
RU2216316C2 (ru)	2003-11-20
HUP0004405A3 (en)	2004-03-29
PL340926A1 (en)	2001-03-12
JP2001524514A (ja)	2001-12-04
NZ504354A (en)	2001-12-21
AR016684A1 (es)	2001-07-25
ZA9810465B (en)	1999-05-21
DE69828527T2 (de)	2005-12-29
WO1999027913A1 (en)	1999-06-10

Publication	Publication Date	Title
SK6592000A3 (en)	2001-01-18	Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances
Sandor et al.	2001	Effect of protein molecular weight on release from micron-sized PLGA microspheres
US6077544A (en)	2000-06-20	Spheroids, preparation process and pharmaceutical compositions
EP2136792B1 (de)	2012-12-26	Heissschmelzmikropellets
CN105828806A (zh)	2016-08-03	制剂
JP2010090146A (ja)	2010-04-22	薬効を有する医薬の含有割合が高いメサラジンサッシェ
CN108159019A (zh)	2018-06-15	非索非那定微胶囊及含有非索非那定微胶囊的组合物
EP1032391B1 (de)	2002-05-15	Tiagabin enthaltende spheroide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
EP1032370B1 (de)	2003-12-17	Poröse hydroxyapatit-partikel als träger für medikamente
JP2014516961A (ja)	2014-07-17	多粒子医薬組成物
US20060115524A1 (en)	2006-06-01	Method for preparation of an agglomerate using melt agglomeration
Hamman et al.	2017	Multiple-unit pellet systems (MUPS): production and applications as advanced drug delivery systems
CZ20001945A3 (cs)	2000-10-11	Pelety z polyethylenglykolové matrice pro mastné, olejové nebo lepivé léčivé substance
MXPA00005112A (en)	2002-03-26	Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances
Nguyen	2017	Extrusion-spheronization of pharmaceutical products: system for the delivery of active ingredients which are poorly soluble by oral route
MXPA00005116A (en)	2002-03-05	Porous hydroxyapatite particles as carriers for drug substances
CZ20001946A3 (cs)	2000-10-11	Porézní částice hydroxyapatitu jako nosiče léčivých substancí